cap-dependent

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

Cap-dependent endonuclease-IN-25 is a macrocyclic pyridoxal derivative and a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with potential for studying viral infections caused by viruses of the Orthomyxoviridae family.

Cap-dependent endonuclease-IN-6 (compound 13) is a Cap-dependent endonuclease (CEN) inhibitor that targets and inhibits the influenza virus.

Cap-dependent endonuclease-IN-19, a spirocyclic pyridinone derivative, is a potent inhibitor of cap-dependent nucleic acid endonuclease (CEN) and effectively inhibits the RNA polymerase activity of influenza A virus.

Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN) and demonstrates research potential against influenza virus infection [influenza A only].

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), effectively inhibiting influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and pharmacodynamic properties, and good hepatic microsomal stability. It has shown investigational potential against viral infections, including influenza A, B, and C.

Cap-dependent endonuclease-IN-11 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with demonstrated research potential for treating viral infections.

Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and demonstrates inhibitory effects on influenza virus replication, showing research potential against influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and effectively inhibits influenza virus replication, demonstrating significant research potential for influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with significant influenza virus inhibitory activity, demonstrating lower cytotoxicity and improved in vivo pharmacokinetic and pharmacodynamic properties.

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and can inhibit the replication of influenza viruses, showing potential for treating viral infections caused by influenza viruses.

Cap-dependent endonuclease-IN-17, a cap-dependent endonuclease (CEN) inhibitor, exhibits antiviral activity against influenza virus A Hanfang 359 95 (H3N2) with an IC50 of 1.29 μM.

Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) that effectively inhibits the replication of orthomyxoviruses, including influenza A, B, and C.

Cap-dependent endonuclease-IN-16, a pyridone polycyclic derivative, is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with potential applications in influenza studies.

Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and significantly inhibits influenza A virus RNA polymerase activity.

Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), demonstrating potential for investigating influenza A and B infections.

Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively inhibiting viral mRNA synthesis and halting virus proliferation, making it especially promising for research into viral infections, including influenza types A, B, and C.

Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor designed for the treatment of influenza A and B virus infections.

AV5124 is a prodrug of AV5116 and acts as an orally active inhibitor of influenza virus cap-dependent endonuclease (CEN).

eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.

CAP 3 is a cholic acid-peptide conjugate (CAP) with antibacterial activity. It is active against the Gram-negative bacteria E. coli, K. pneumoniae, and A. baumanii (MIC99s = 8, 16, and 16 μM, respectively). CAP 3 increases the fluidity of model Gram-negative bacterial membranes and binds to LPS in vitro. It reduces the biomass and number of colony-forming units in E. coli biofilms in a concentration-dependent manner. CAP 3 inhibits E. coli biofilm formation on catheters implanted in mice infected with E. coli at the incision site when applied as a coating on the catheters. CAP 3 (40 mg/kg) also reduces bacterial load in E. coli-infected wounds in mice. It is cytotoxic to A459 cells (IC50 = 56.4 μM) and has hemolytic activity against human red blood cells with a 50% lysis (HC50) value of 48 μM.

Influenza virus-IN-7 (Example 16) is an orally active cap-dependent endonuclease inhibitor used in influenza viral infectious disease research [1].